--- title: "OSR Health receives Nasdaq delisting determination" url: "https://aibio.space/news/osr-health-receives-nasdaq-delisting-determination-will-request/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2026-08-19" section: "Listings" tickers: "OTC:OSRH" source: "https://www.sec.gov/Archives/edgar/data/1840425/000121390026091756/ea030278201ex99-1.htm" summary: "Nasdaq staff said OSR Health did not regain compliance with the $1.00 minimum bid price, and trading in its common stock and warrants will be suspended on" --- By the aibio.space news desk. Sources - [OSR Health, Inc. 8-K (2026-08-19)](https://www.sec.gov/Archives/edgar/data/1840425/000121390026091756/ea030278201ex99-1.htm) - [OSR Health, Inc. 10-K (2026-03-31): business](https://www.sec.gov/Archives/edgar/data/1840425/000121390026037395/ea0283154-10k_osrhold.htm) - [OSR Health, Inc. financial data (SEC XBRL)](https://www.sec.gov/Archives/edgar/data/1840425/000121390026037395/) [OSRH](https://aibio.space/companies/osr-health/) 2026-08-19 # OSR Health receives Nasdaq delisting determination, will request hearing Tickers [OSRH](https://aibio.space/companies/osr-health/) Nasdaq staff said OSR Health did not regain compliance with the $1.00 minimum bid price, and trading in its common stock and warrants will be suspended on August 26, 2026. ## Key facts - **Company**: OSR Health, Inc. (OTC: OSRH) - **News type**: Listings - **Primary source**: [OSR Health, Inc. 8-K (2026-08-19)](https://www.sec.gov/Archives/edgar/data/1840425/000121390026091756/ea030278201ex99-1.htm) *The Capitol dome and spring blossom. Photo: Angie Drake, CC0, via Wordpress. The picture shows the field, not the companies named.* OSR Health, Inc. said on August 19, 2026 that it received a written Staff Delisting Determination from the Nasdaq Listing Qualifications Department. The determination states that the company's common stock and warrants are subject to delisting from The Nasdaq Capital Market because the company did not regain compliance with the minimum bid price requirement of Nasdaq Listing Rule 5550(a)(2). The company announced the determination in a press release filed as Exhibit 99.1 to a Form 8-K filed the same day. The company said it intends to request a hearing before the Nasdaq Independent Hearings Panel to appeal the staff determination. It said the appeal would follow the procedures in the Nasdaq Listing Rule 5800 Series. ## The compliance history According to the release, the company was first notified of its non-compliance with the minimum bid price requirement on September 5, 2025. It was then given an initial 180-calendar-day compliance period through March 4, 2026. On March 5, 2026, it received an additional 180-calendar-day compliance period through August 31, 2026. The staff determination states that the company did not regain compliance during that applicable period. ## The trading figures the company cites The company argued that trading activity on August 17 and 18, 2026 supports its case. It said OSRH ranked first in Most Active Share Volume across Nasdaq on August 17, with approximately 370 million shares traded. On August 18 it ranked third, with approximately 145 million shares traded. The company said its public float is approximately 18.5 million shares, which means the market traded its entire public float more than twenty times in a single day. The release also says the share price reached an intraday high of $0.84 on August 18, sixteen cents below the $1.00 compliance threshold, before declining in the final hours of trading. The company said these market dynamics, along with the circumstances behind the compliance shortfall, represent a compelling basis for the Panel's consideration. Those are the company's own statements. The release does not include any analysis by Nasdaq of those trading figures. ## Trading suspension The release says the company used the second 180-day compliance period under Nasdaq rules, so a timely hearing request will not automatically stay the trading suspension. The common stock, which trades as OSRH, and the warrants, which trade as OSRHW, are to be suspended from trading on The Nasdaq Capital Market at the opening of business on August 26, 2026. The company's background report describes it as a holding company with operations in South Korea and Switzerland and an office in the United States. The annual report for 2025, filed March 31, 2026, lists three subsidiaries, two with drug development pipelines, one in oral T-cell immunotherapies and one in a design-augmented recombinant biologic for bone and cartilage regeneration, along with a neurovascular surgical device business. ## Financial position SEC XBRL data show revenue of $2.9 million for fiscal 2025 and $3.5 million for fiscal 2024. Research and development expense was $318,446 in 2025 and $161,155 in 2024. Cash from operations was negative $4.3 million in 2025 and negative $1.8 million in 2024. The fiscal 2024 net loss was $2.4 million. Year-end 2025 cash and cash equivalents were $1.7 million, according to a 10-Q filed August 14, 2026. ## The risks ahead The company has to win an appeal, and it has said so itself: the release states there can be no assurance that the Panel will grant continued listing or reinstatement of trading. Because it used the second 180-day compliance period, the suspension from the opening of business on August 26, 2026 is not stayed by a hearing request. Its share price reached an intraday high of $0.84 on August 18, below the $1.00 threshold, and the filings show it never regained compliance after the first notice on September 5, 2025. Cash from operations was negative $4.3 million in 2025 against year-end cash and cash equivalents of $1.7 million. The next disclosure on the matter would be the Panel's decision. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story OSRH OSR Health, Inc. OTC ยท United States Open the starter desk ## More in Listings Listings ### [Propanc Biopharma faces Nasdaq delisting on bid price, plans to appeal](https://aibio.space/news/propanc-biopharma-faces-nasdaq-delisting-bid-price-plans-appeal/) Oct 29, 2026 Listings ### [Reviva asks stockholders to approve reverse split of up to 1-for-100](https://aibio.space/news/reviva-asks-stockholders-approve-reverse-split-up-1-100/) Oct 29, 2026 Listings ### [Nasdaq to delist Glucotrack shares after bid price exception ends](https://aibio.space/news/nasdaq-delist-glucotrack-shares-after-bid-price-exception-ends/) Oct 28, 2026 --- Source page: https://aibio.space/news/osr-health-receives-nasdaq-delisting-determination-will-request/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "OSR Health receives Nasdaq delisting determination", 2026-08-19, https://aibio.space/news/osr-health-receives-nasdaq-delisting-determination-will-request/